On the International Day of Happiness, Finland Calls for International Business Cooperation to Solve Major Global Challenges Together
20.3.2025 01:15:00 CET | Business Wire | Press release
Societal stability, high levels of equality and, among other things, political and civil freedom are frequently highlighted as the key factors contributing to Finland's status as the world’s happiest country in recent years, as reflected in the World Happiness Report. These are the building blocks of the trust and mutual respect that permeate Finnish society, enabling innovative international cooperation and providing an excellent launchpad for business.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250319812998/en/
Photo credits: Svante Gullichsen & Visit Finland
In Finnish society, there are many factors that underscore succeeding together: an education system that emphasizes teamwork and collective problem-solving, flat hierarchies in organizations and a society that encourages participation, a culture that values consensus and cooperation over individual competition, and social safety nets that provide security, allowing for risk-taking. This creates an environment where it is safe to engage in innovation and seize the opportunities life offers.
Collaboration is the power to change the world
The strong collaboration between the public and private sectors forms the backbone of Finland’s innovation economy. Industries, research institutes, universities, and the government together have a unique ability to deliver disruptive technologies and innovative design. Finland consistently ranks among the world’s leading countries in education, innovation, digitalization, sustainability, and good governance, making it one of the world’s hotspots for R&D. To give it a further boost, Finland aims to increase research and development expenditure to 4% of GDP by 2030.
Finland boasts a thriving startup scene with an estimated number of 3 800 startups. The Finnish startup ecosystem has always been about pooling resources, lending a hand, and helping one another. When one business is successful, it benefits the whole network – a rising tide lifts all boats. Finland's startup ecosystem has given birth to more than 10 unicorns, many of which stem from academia.
An example of open-minded cooperation in building R&D is the Leading Companies Program. Here, Business Finland challenges global companies to undertake ambitious research efforts while encouraging companies of different sizes and other players to work together, sharing knowledge and resources, aiming to achieve breakthroughs that solve major global challenges – and do business. So far, the scheme has supported 400 companies in Finland and 400 research projects by universities and other research institutes. The Leading Companies Program is open to international companies that have a subsidiary in Finland.
Finland invites you to innovate in the state of happiness
Collaboration with Finns is defined by sisu – a uniquely Finnish concept of integrity-driven determination and courage under pressure. It means acting with deep resolve while upholding a strong commitment to mutual respect among collaborators. Promises are kept, and things are done well even when no one is watching.
Johanna Jäkälä, Executive Director, Finland Promotion Services from Business Finland says:
“Collaboration, along with sisu, is really in the DNA of Finland. No one creates change alone, and that is why we are committed to bringing people and businesses together to team up, make unexpected connections, solve problems together, and create an impact.”
For the 8th year in a row, Finland has been named the happiest country in the world by the annual United Nations World Happiness Report*, holding the top title since 2018.
ABOUT
Business Finland is the Finnish government organization for innovation funding and trade, travel, and investment promotion. Business Finland’s over 760 experts work in over 40 offices globally and in 16 regional offices around Finland. Business Finland is part of the Team Finland network. www.businessfinland.com
Invest in Finland helps foreign companies identify business opportunities in Finland, produces information on Finland as an investment destination, and enhances and coordinates national efforts to attract investment by actively networking with regional and international entities. Invest in Finland also collects and updates information about foreign-owned companies in Finland. Invest in Finland is part of Business Finland.
Work in Finland attracts talents and startup founders to Finland and help companies to recruit international professionals. www.workinfinland.com is a national website for talent attraction.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250319812998/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom